Apoptosis induction by retinoids in eosinophilic leukemia cells: Implication of retinoic acid receptor-α signaling in all-trans-retinoic acid hypersensitivity

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6336-6344

  Robert, Carine ^a   Delva, Laurent ^a   Balitrand, Nicole ^a   Nahajevszky, Sarolta ^b   Masszi, Tamàs ^b   Chomienne, Christine ^a   Papp, Béla ^a,c  

^a INSERM   (France)

^b NATIONAL MEDICAL CENTER   (Hungary)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; PHOSPHATIDYLSERINE; PROTEIN BAK; PROTEIN BCL 2; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID DERIVATIVE;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; EOSINOPHIL; EOSINOPHILIC LEUKEMIA; EX VIVO STUDY; HUMAN; HUMAN CELL; HYPEREOSINOPHILIA; HYPERSENSITIVITY; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MYELOID LEUKEMIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; DRUG HYPERSENSITIVITY; EOSINOPHILS; HL-60 CELLS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; RECEPTORS, RETINOIC ACID; SIGNAL TRANSDUCTION; STEM CELLS; TRETINOIN;

EID: 33745728145     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0078     Document Type: Article

References (57)

1. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997;24:92-102.
2. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRα and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
3. Coutré SE, Gotlib J. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 2004;14:307-15.
4. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8.
5. Gotlib J, Cools J, Malone JM III, et al. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-91.
6. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRα fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-45.
7. Tauchi T, Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 2004;28 Suppl 1:S39-45.
8. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002;16:1940-58.
9. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003;3:459-69.
10. Tomonaga M, Gasson JC, Quan SG, Golde DW. Establishment of eosinophilic sublines from human promyelocytic leukemia (HL-60) cells: demonstration of multipotentiality and single-lineage commitment of HL-60 stem cells. Blood 1986;67:1433-41.
11. Paul CC, Tolbert M, Mahrer S, et al. Cooperative effects of interleukin-3 (IL-3), IL-5, and granulocyte-macrophage colony-stimulating factor: a new myeloid cell line inducible to eosinophils. Blood 1993;81:1193-9.
12. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EoL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003;100:7830-5.
13. Mayumi M. EoL-1, a human eosinophilic cell line. Leuk Lymphoma 1992;7:243-50.
14. Saito H, Bourinbaiar A, Ginsburg M, et al. Establishment and characterization of a new human eosinophilic leukemia cell line. Blood 1985;66:1233-40.
15. Cools J, Quentmeier H, Huntly BJ, et al. The EoL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRα-positive chronic eosinophilic leukemia. Blood 2004;103:2802-5.
16. Wong CK, Ho CY, Lam CW, Zhang JP, Hjelm NM. Differentiation of a human eosinophilic leukemic cell line, EoL-1: characterization by the expression of cytokine receptors, adhesion molecules, CD95, and eosinophilic cationic protein (ECP). Immunol Lett 1999;8:317-23.
17. Shintaku N, Ohshima Y, Jung EY, et al. Induction of eosinophilic granules, nonspecific esterase activity and CD14 expression in the human eosinophilic leukemia cell line, EoL-1. Hematol Oncol 1994;12:129-39.
18. Gilliland G, Cools J, Stover EH, Wlodarska I, Marynen P. FIP1L1-PDGFRα in hypereosinophilic syndrome and mastocytosis. Hematol J 2004;5:S133-7.
19. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
20. Upham JW, Sehmi R, Hayes LM, et al. Retinoic acid modulates IL-5 receptor expression and selectively inhibits eosinophil-basophil differentiation of hemopoietic progenitor cells. J Allergy Clin Immunol 2002;109:307-13.
21. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
22. Korchak HM, Rich AM, Wilkenfeld C, Rutherford LE, Weissmann G. A carbocyanine dye, DiOC6(3), acts as a mitochondrial probe in human neutrophils. Biochem Biophys Res Commun 1982;108:1495-501.
23. Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature 1988;336:262-5.
24. Delva L, Bastie JN, Rochette-Egly C, et al. Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. Mol Cell Biol 1999;19:7158-67.
25. Gélébart P, Kovács T, Brouland JP, et al. Expression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation. J Biol Chem 2002;277:26310-20.
26. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990;79:448-53.
27. Taimi M, Breitman TR. Growth, differentiation, and death of retinoic acid-treated human acute promyelocytic leukemia NB4 cells. Exp Cell Res 1997;230:69-75.
28. Jung EY, Ohshima Y, Shintaku N, et al. Effects of cyclic AMP on expression of LFA-1, Mac-1, and VLA-4 and eosinophilic differentiation of a human leukemia cell line, EoL-1. Eur J Haematol 1994;53:156-62.
29. Alam R, Forsythe P, Stafford S, Fukuda Y. Transforming growth factor β abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994;179:1041-5.
30. Druilhe A, Cai Z, Haile S, Chouaib S, Pretolani M. Fas-mediated apoptosis in cultured human eosinophils. Blood 1996;87:2822-30.
31. Cory S, Adams JM. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
32. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67.
33. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 β, a mammalian homologue of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
34. Pászty K, Verma AK, Padányi R, et al. Plasma membrane Ca2+ATPase isoform 4b is cleaved and activated by caspase-3 during the early phase of apoptosis. J Biol Chem 2002;277:6822-9.
35. Minucci S, Pelicci PG. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999;10:215-25.
36. Giannì M, Li Calzi M, Terao M, et al. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood 1996;87:1520-31.
37. Apfel C, Bauer F, Crettaz M, et al. A retinoic acid receptor α antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A 1992;89:7129-33.
38. Kopf E, Plassat JL, Vivat V, et al. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors α and γ through the ubiquitin-proteasome pathway. J Biol Chem 2000;275:33280-8.
39. Al-Rabia MW, Blaylock MG, Sexton DW, Thomson L, Walsh GM. Granule protein changes and membrane receptor phenotype in maturing human eosinophils cultured from CD34+ progenitors. Clin Exp Allergy 2003;33:640-8.
40. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980;77:2936-40.
41. Lanotte M, Martin-Thouvenin V, Najman S, et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-6.
42. Doyle LA, Giangiulo D, Hussein A, et al. Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. Cancer Res 1989;49:6745-51.
43. Pfahl M, Piedrafita FJ. Retinoid targets for apoptosis induction. Oncogene 2003;22:9058-62.
44. Liu Y, Lee MO, Wang HG, et al. Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 1996;16:1138-49.
45. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-γ and altered expression of Bcl-2/Bax. Br J Cancer 2002;87:555-61.
46. Park JR, Robertson K, Hickstein DD, et al. Dysregulated bcl-2 expression inhibits apoptosis but not differentiation of retinoic acid-induced HL-60 granulocytes. Blood 1994;84:440-5.
47. Calabresse C, Barbey S, Venturini L, et al. In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. Leukemia 1995;9:2049-57.
48. Notario B, Zamora M, Viñas O, Mampel T. All-transretinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol Pharmacol 2003;63:224-31.
49. Schmidt-Mende J, Gogvadze V, Hellström-Lindberg E, Zhivotovsky B. Early mitochundrial alterations in ATRA-induced cell death. Cell Death Differ 2006;13:119-28.
50. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calciumapoptosis link. Nat Rev Mol Cell Biol 2003;4:552-65.
51. Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680-6.
52. Tai G, Eun-Young J, Yuji H, et al. Different effects of cyclic AMP and butyrate on eosinophilic differentiation, apoptosis and bcl-2 expression of a human eosinophilic leukemia cell line, EoL-1. Hematol Oncol 1996;14:181-92.
53. Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c -induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002;9:1046-56.
54. Van de Craen M, Declercq W, Van den brande I, Fiers W, Vandenabeele P. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ 1999;6:1117-24.
55. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5.
56. Wedi B, Straede J, Wieland B, Kapp A. Eosinophil apoptosis is mediated by stimulators of cellular oxidative metabolisms and inhibited by antioxidants: involvement of a thiol-sensitive redox regulation in eosinophil cell death. Blood 1999;94:2365-73.
57. Cambier N, Menot ML, Schlageter MH, et al. All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronic myelomonocytic leukaemia. Hematol J 2001;2:97-102.